# Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies

> **NCT03987685** · PHASE1 · COMPLETED · sponsor: **Athenex, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Oratopo

## Key facts

- **NCT ID:** NCT03987685
- **Lead sponsor:** Athenex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-19
- **Primary completion:** 2021-01-09
- **Final completion:** 2021-01-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03987685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03987685, "Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03987685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*